Tag: Advanced
Conclusions S-1 plus docetaxel combination therapy in an outpatient setting provided promising activity with acceptable adverse toxicities.
Content Type Journal ArticleDOI 10.1007/s00280-010-1433-7Authors
Chikara Kunisaki, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanMasazumi Takahashi, Department of Surgery, Yokohama Municipal Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-0062 JapanHirochika Makino, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanTakashi Oshima, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanShoichi …
Source: MedWorm: Oral Cancer
Tags: Advanced, Biweekly, Cancer, chemotherapy., Combination, docetaxel, FirstLine, Gastric, Phase, Study, Treatment
Posted in Treatment | No Comments »
Conclusion The SOx regimen evidenced a relatively high response rate and was well tolerated as a first-line therapy for advanced gastric
cancer.
Content Type Journal ArticleDOI 10.1007/s10637-010-9507-2Authors
Sung Yong Oh, Department of Internal Medicine, Dong-A University College of Medicine, Busan, KoreaHyuk-Chan Kwon, Department of Internal Medicine, Dong-A University College of Medicine, Busan, KoreaSang-Ho Jeong, Departments of Surgery, Gyeongsang National University Hospital, Jinju, South KoreaYoung-Tae Joo, Departments of Surgery, Gyeongsang National University Hospital, Jinju, South KoreaYoung-Joon Lee, Departments of Surgery, Gyeongsang National University Hospital, Jinju, South KoreaSu hee Cho, Departments of Internal Medicine, Gyeongsang National University Hospital, Ji…
Source: MedWorm: Oral Cancer
Tags: Advanced, Cancer, chemotherapy., Combination, FirstLine, Gastric, oxaliplatin, patients, Phase, Study, therapy
Posted in Treatment | No Comments »
DISCUSSION: Sunitinib continuous-dosing with 25 mg/day can safely be combined with CetIri administered every other week.
PMID: 20615171 [PubMed - in process] (Source: Acta Oncologica)
Source: MedWorm: Oral Cancer
Tags: addition, Advanced, Cancer, cetuximab, Colorectal, heavily, irinotecan, patients, pretreated, Sunitinib
Posted in Treatment | No Comments »
Conclusion Increasing the dose of radiation by HDR brachytherapy boost appears to improve the RO resection and pCR rates compared with conventional CRT. The follow up is too short to judge its effect on disease-free survival. This study will be extended to compare this strategy in a randomized phase III trial with conventional CRT in patients who are not fit for more intensive CRT (HERCULES). (Source: Colorectal Disease)
Source: MedWorm: Oral Cancer
Tags: Advanced, boost, Brachytherapy, Cancer, chemoradiotherapy, Dose, following, improve, increasing, OPERATIVE, Outcomes, radiation, rectal, Surgical
Posted in Treatment | No Comments »
Source: Lancet
Area: News
Olaparib is an orally active poly(ADP-ribose) polymerase (PARP) inhibitor which induces lethality in BRCA-deficient cells. Two phase II Astra Zeneca sponsored studies have assessed its efficacy and safety in women with BRCA1 or BRCA2 mutations, and advanced breast- or recurrent ovarian cancer.
In the studies, women aged ?18 years (median of three previous chemotherapy regimens) were assigned to two sequential cohorts: the first cohort (n=27 breast, n= 33 ovarian) was given continuous oral olaparib at the maximum tolerated dose (400mg BD), and the second (n=27 breast, n= 24, ovarian) was given a lower dose (100mg BD). The primary efficacy endpoint was objective response rate (ORR).
Amongst the breast cancer group:
. The ORR wa…
Source: MedWorm: Oral Cancer
Tags: Advanced, BRCA1, BRCA2, Breast, Cancer, Horizon, Inhibitor, mutations, olaparib, Oral, Ovarian, patients, PolyADPRibose, Polymerase, recurrent, scanning
Posted in Treatment | No Comments »
Targeted oral treatment effectively slows down the progression of advanced RCC whilst maintaining patientsâ quality of life (Source: Pharmacy Europe)
Source: MedWorm: Oral Cancer
Tags: Advanced, Available, carcinoma, cell, Pazopanib, renal, Treatment, Votrient
Posted in Treatment | No Comments »
The experience suggests that the first 4 weeks of treatment is the most likely timeframe within which drug reactions occur. Therefore, careful monitoring and possibly additional clinical visits are warranted during this time period. Although a significant percentage of patients require dose modification, many can be restarted and titrated up to the targeted dose.06/27/2010 (Source: Kidney Cancer Association)
Source: MedWorm: Oral Cancer
Tags: Advanced, carcinoma, cell, Dose, Frequent, Inhibitor, Interruptions, Kinase, Oral, patients, Receiving, renal, Required, therapy
Posted in Treatment | No Comments »
Conclusions: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC. No drug–drug interaction was detected and there was preliminary evidence of antitumor activity. (Source: Annals of Oncology)
Source: MedWorm: Oral Cancer
Tags: Advanced, Breast, Cancer, exploratory, FirstLine, Paclitaxel, patients, plus, Study, Sunitinib, Treatment
Posted in Treatment | No Comments »
Angiogenesis inhibitors have demonstrated significant clinical efficacy in mRCC. Pazopanib and sunitinib are both oral tyrosine kinase inhibitors primarily of VEGFR (-1, -2, and -3), PDGFR (-a and -b) and c-Kit. Pazopanib has a more selective kinase specificity profile compared to sunitinib and has demonstrated low rates of fatigue, hand foot syndrome and mucositis/stomatitis. There is an ongoing phase III head to head study of pazopanib vs. sunitinib in treatment naïve mRCC patients (pts). The outcomes of cancer therapy are traditionally evaluated using RECIST response and survival criteria. There is increasing emphasis on assessment of health related quality of life (HRQoL) particularly relevant to tolerability of agents. However, HRQoL questionnaires might not reflect the pt preference…
Source: MedWorm: Oral Cancer
Tags: Advanced, carcinoma, cell, crossover, doubleblind, Locally, Metastatic, Patient, Pazopanib, preference, randomized, renal, Study, Sunitinib, treatmentnaive, versus
Posted in Treatment | No Comments »
Up to 2,000 UK patients denied NHS access to Tyverb
LONDON, June 9, 2010-Today the National Institute for Health and
Clinical Excellence (NICE) issued its Final Appraisal Determination
(FAD) advising against NHS funding for oral Tyverb (lapatinib)… (Source: Drugs.com – Pharma News)
Source: MedWorm: Oral Cancer
Tags: Advanced, Against, Breast, Cancer, Effective, Funding, Lapatinib, NICE, Rules, Treatment, Tyverb
Posted in Treatment | No Comments »
